The End of Aspirin for Anticoagulated Patients Undergoing PCI

The discussion about the best anti-thrombotic strategy for patients with atrial fibrillation undergoing PCI seemed never-ending until the RE-DUAL PCI trial was published in the New England Journal of Medicine (NEJM). This study has arrived to simplify the tough choice between the risk of a thrombotic event vs. the risk of bleeding with a simpler scheme, without giving up efficacy and gaining in safety.

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

2725 patients with atrial fibrillation undergoing PCI were randomized to a triple scheme with warfarin + a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin (between 1 and 3 months) vs. a dual scheme with dabigatran (110 mg or 150 mg twice a day) plus a P2Y12 inhibitor (clopidogrel or ticagrelor), without aspirin.


Read also: Fentanyl in Angioplasty: What Is the Price of More Comfort During the Procedure?”


Outside the United States, elderly patients (≥80 years of age, or ≥70 years of age in Japan) received 110-mg dabigatran twice a day.

 

Primary end point was major bleeding or clinically relevant minor bleeding at 14 month mean follow up. The study also tested non inferiority as regards thrombotic events (acute myocardial infarction, stroke or systemic embolism), death or unplanned revascularization.

 

The incidence of primary end point was 15.4% for 110 mg for the dual scheme vs. 26.9% for the triple scheme (HR, 0.52; CI 95%, 0.42 to 0.63; p<0.001 for non inferiority and p<0.001 for superiority). The dual antithrombotic therapy with 150 mg dabigatran had 20.2% event rate, compared to 25.7% of the triple scheme, which did not include elderly patients outside the US (HR, 0.72; CI 95%, 0.58 to 0.88; p<0.001 for non inferiority).


Read also: MitraClip Procedure Can Be Performed without General Anesthesia”.


The combined efficacy end point was 13.7% for the dual scheme vs. 13.4% for the triple scheme (p=0.005 for non inferiority).

 

Adverse events rate was similar between both groups.

 

Conclusion

In patients with atrial fibrillation that must be anticoagulated also undergoing PCI, dual therapy with dabigatran plus a P2Y12 inhibitor was significantly safer than the triple scheme with warfarin, P2Y12 inhibitor and aspirin. Regarding thrombotic events, both strategies resulted similar.

 

Editorial Comment

The lower rate of bleeding is on the same line as the one observed in the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). However, it seems amplified in this population, with higher risk of bleeding, where aspirin was discontinued at randomization.

 

The RE-DUAL PCI is the largest randomized trial to validate the WOEST trial (What is the Optimal Antiplatelet and Anticoagulant Therapy in Patients with Oral Anticoagulation and Coronary Stenting), with enough statistical power to be considered definitive.

 

Título original: Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Referencia: Christopher P. Cannon et al. N Engl J Med. 2017 Oct 19;377(16):1513-1524.


Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

Su opinión nos interesa. Puede dejar su comentario, reflexión, pregunta o lo que desee aquí abajo. Será más que bienvenido.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...